MX2018010640A - Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad. - Google Patents
Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.Info
- Publication number
- MX2018010640A MX2018010640A MX2018010640A MX2018010640A MX2018010640A MX 2018010640 A MX2018010640 A MX 2018010640A MX 2018010640 A MX2018010640 A MX 2018010640A MX 2018010640 A MX2018010640 A MX 2018010640A MX 2018010640 A MX2018010640 A MX 2018010640A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- glucagon
- obesity
- agonists
- treatment
- Prior art date
Links
- 108060003199 Glucagon Proteins 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se proporcionan métodos para prevenir y tratar la obesidad y la diabetes en pacientes, que comprenden administrar péptidos agonistas de GLP-1/glucagón.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306121P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2017/055679 WO2017153575A1 (en) | 2016-03-10 | 2017-03-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010640A true MX2018010640A (es) | 2019-06-13 |
Family
ID=58266629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010640A MX2018010640A (es) | 2016-03-10 | 2017-03-10 | Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10676517B2 (es) |
| EP (1) | EP3426284B1 (es) |
| JP (2) | JP7237590B6 (es) |
| KR (2) | KR102460198B1 (es) |
| CN (1) | CN108697769A (es) |
| AR (1) | AR107890A1 (es) |
| AU (2) | AU2017229530B2 (es) |
| BR (1) | BR112018067731A2 (es) |
| CA (1) | CA3015922A1 (es) |
| EA (1) | EA201891946A1 (es) |
| ES (1) | ES2983409T3 (es) |
| IL (1) | IL261528B2 (es) |
| MX (1) | MX2018010640A (es) |
| MY (1) | MY191321A (es) |
| NZ (1) | NZ746784A (es) |
| SG (2) | SG11201806342SA (es) |
| TW (1) | TWI793069B (es) |
| WO (1) | WO2017153575A1 (es) |
| ZA (1) | ZA201806637B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202193102A1 (ru) * | 2019-05-21 | 2022-02-17 | Медиммун Лимитед | Инъекционные совместные составы на основе циклодекстрина, содержащие ингибиторы sglt2 и инкретиновые пептиды |
| CR20220046A (es) * | 2019-07-01 | 2022-03-24 | Medimmune Ltd | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 |
| EP4017866A1 (en) | 2019-08-19 | 2022-06-29 | Eli Lilly and Company | Methods of making incretin analogs |
| EP4069720A4 (en) * | 2019-12-03 | 2023-12-27 | MedImmune, LLC | COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY |
| TWI795698B (zh) | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TW202140061A (zh) | 2020-01-10 | 2021-11-01 | 英商梅迪繆思有限公司 | 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑 |
| EP4090351A4 (en) * | 2020-01-16 | 2023-09-13 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| MX2022013230A (es) | 2020-04-24 | 2022-11-14 | Boehringer Ingelheim Int | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. |
| CA3201539A1 (en) * | 2020-12-07 | 2022-06-16 | Vyjayanthi Krishnan | Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| KR20240043778A (ko) | 2021-07-30 | 2024-04-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법 |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
| WO2024252366A1 (en) | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| KR20250067206A (ko) | 2023-11-07 | 2025-05-15 | 주식회사 천농바이오푸드 | 대사성 질환의 예방, 개선 또는 치료 효과를 갖는 채소 추출복합물 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| AU2008266448B2 (en) | 2007-06-21 | 2013-06-13 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or vitro stability |
| FR2932484B1 (fr) | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
| RU2012136450A (ru) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| EP3028720A1 (en) * | 2010-09-28 | 2016-06-08 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
| CN103402536A (zh) * | 2010-12-22 | 2013-11-20 | 马克迪亚生物科技公司 | 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法 |
| EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| TWI674270B (zh) * | 2012-12-11 | 2019-10-11 | 英商梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
| MX2015008114A (es) * | 2012-12-21 | 2015-11-06 | Sanofi Sa | Derivados de exendina-4. |
-
2017
- 2017-03-10 TW TW106108066A patent/TWI793069B/zh not_active IP Right Cessation
- 2017-03-10 CN CN201780013643.1A patent/CN108697769A/zh active Pending
- 2017-03-10 MY MYPI2018703199A patent/MY191321A/en unknown
- 2017-03-10 CA CA3015922A patent/CA3015922A1/en active Pending
- 2017-03-10 ES ES17710231T patent/ES2983409T3/es active Active
- 2017-03-10 EA EA201891946A patent/EA201891946A1/ru unknown
- 2017-03-10 EP EP17710231.6A patent/EP3426284B1/en active Active
- 2017-03-10 US US16/083,064 patent/US10676517B2/en active Active
- 2017-03-10 JP JP2018546872A patent/JP7237590B6/ja active Active
- 2017-03-10 MX MX2018010640A patent/MX2018010640A/es unknown
- 2017-03-10 SG SG11201806342SA patent/SG11201806342SA/en unknown
- 2017-03-10 KR KR1020187028772A patent/KR102460198B1/ko active Active
- 2017-03-10 IL IL261528A patent/IL261528B2/en unknown
- 2017-03-10 SG SG10202109721P patent/SG10202109721PA/en unknown
- 2017-03-10 AU AU2017229530A patent/AU2017229530B2/en not_active Ceased
- 2017-03-10 AR ARP170100613A patent/AR107890A1/es unknown
- 2017-03-10 NZ NZ746784A patent/NZ746784A/en not_active IP Right Cessation
- 2017-03-10 KR KR1020227037091A patent/KR20220150416A/ko not_active Ceased
- 2017-03-10 WO PCT/EP2017/055679 patent/WO2017153575A1/en not_active Ceased
- 2017-03-10 BR BR112018067731A patent/BR112018067731A2/pt not_active IP Right Cessation
-
2018
- 2018-10-05 ZA ZA2018/06637A patent/ZA201806637B/en unknown
-
2020
- 2020-04-03 AU AU2020202381A patent/AU2020202381A1/en not_active Abandoned
- 2020-04-22 US US16/855,552 patent/US20200354426A1/en not_active Abandoned
-
2021
- 2021-08-26 US US17/412,811 patent/US20220041681A1/en not_active Abandoned
-
2022
- 2022-11-04 JP JP2022177486A patent/JP2023011864A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010640A (es) | Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad. | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| HK1220383A1 (zh) | 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂 | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
| PH12017502359B1 (en) | Glucagon and glp-1 co-agonist compounds | |
| MY208231A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| CY1124616T1 (el) | Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39) | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| PH12017501509B1 (en) | Tesofensine, beta blocker combination formulation | |
| MX366685B (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| TN2016000498A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine. | |
| IL281016A (en) | Methods to reduce the risk of diabetes in patients treated for diseases related to high cholesterol | |
| PL3139948T3 (pl) | Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 | |
| DK3366306T3 (en) | Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto | |
| HK40081995A (en) | Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity | |
| EP4069720A4 (en) | COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY | |
| HK1261360A1 (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| UA104615U (uk) | Спосіб лікування токсокарозу | |
| UA93627U (uk) | Спосіб лікування хронічного набутого токсоплазмозу у дорослих | |
| BR112017006190A2 (pt) | agentes terapêuticos humanos |